Skip to content

Study Details

Lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

(IRB#: IRB_00145070)

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3 and consists of 2 sequential parts, Part 1 and Part 2, with the following primary objectives and primary endpoint for the definition of treatment effects.

I AM INTERESTED

  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Will I be paid for my time?

Yes

For more information contact:

Sophia Schuman

sophia.schuman@hsc.utah.edu

  801-581-7802

IRB#: IRB_00145070

PI: Juan Gallegos-Orozco

Department: GASTROENTEROLOGY

Approval Date: 2022-06-08 06:00:00

Specialties: Gastroenterology

Last Updated: 6/8/23